Partnership struck to increase production of DEA controlled substances
Noramco selects AFC for its infrastructure and analytical capabilities to help meet growing demand.
Noramco, a producer of controlled substances for the pharmaceutical industry, and AMPAC Fine Chemicals (AFC), a manufacturer of APIs with cGMP facilities in the US, has announced a strategic partnership to produce certain US DEA controlled substances for use in the treatment of addiction, abuse prevention, cannabinoids for clinical indications, and for the treatment of attention deficit hyperactivity disorder (ADHD).
Noramco will continue to be the marketer and will utilize AFC as the contract manufacturer to supplement existing Noramco capacity.
The DEA Schedule II and III controlled substance APIs are bulk actives for regulated pharmaceutical finished dose customers. These drug substances require high-quality cGMP production assets and sophisticated analytical equipment to meet very precise quality requirements.
AFC recently registered its large-scale controlled substance manufacturing plant in Petersburg, VA, with the DEA further adding to existing state-of-the-art controlled substance manufacturing capabilities at Rancho Cordova, California. The Virginia facility gives Noramco the extra capacity it needs to meet growing demand, and a support facility to complement its in-house capabilities in Wilmington, Delaware.
Noramco President and CEO, James Mish said: “We investigated a number of sites and partners but only AFC has both the infrastructure and analytical capabilities in place that not only meet but exceed our expectations. AFC operates with excellence in both quality and reliability.”
“AFC brings core capabilities like our own. It’s the first company we have found that integrates well with Noramco’s operations and strategic focus. As the abuse deterrence, cannabinoids, and ADHD markets expand and diversify, be it new compounds, or development of traditional products for use in novel delivery systems, Noramco is making new innovations possible for customers, providing everything that’s required to go to market reliably, safely, and on schedule,” Mish said.
Dr Aslam Malik, President and CEO of AMPAC Fine Chemicals, added: “AFC has enjoyed a long-standing relationship with Noramco in supporting the production of their controlled substances. AFC's strategic objective is value-created growth achieved by continuing to serve our key customers through excellent relationship management, by expanding our product lines, and applying our core technologies to their critical needs.”
“The foundation of this growth is established through AFC's Core strengths in Process R&D and Process Engineering. Noramco’s demonstrated commitment to excellence in their products, people and customer support closely aligns with AFC’s. We are delighted to be in partnership with Noramco,” Malik said.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance